Acorda Therapeutics, Inc. (ACOR) NASDAQ

0.66

-0.209(-24.02%)

Updated at April 11, 2024 04:00PM

Currency In USD

Acorda Therapeutics, Inc.

Address

420 Saw Mill River Road

Ardsley, NY 10502

United States of America (the)

Phone

914 347 4300

Website

https://www.acorda.com

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

102

First IPO Date

February 10, 2006

Key Executives

Name	Title	Pay	Year Born
Ron Cohen	Founder, Chief Executive Officer, President & Director	984,150	1956
Michael A. Gesser	Chief Financial Officer	459,150	1963
Kerry Clem	Chief Commercial Officer	592,225	1970
Neil S. Belloff	General Counsel & Corporate Secretary	0	1960
Andrew Mayer	Senior Vice President	0	N/A
Robert Morales	Interim Principal Accounting Officer, Principal Financial Officer, Vice President of Finance & Controller	0	1968
Denise J. Duca	Executive Vice President of Human Resources	0	N/A
Felicia Vonella	Vice President of Investor Relations	0	N/A
Tierney Saccavino	Executive Vice President of Corporation Communications	0	N/A
Sofia Ali	Senior Vice President of Operations & Strategic Planning	0	N/A

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.